AstraZeneca confirms COVID-19 vaccine efficacy again
AstraZeneca has confirmed data on the safety and efficacy of its COVID-19 vaccine that were published on March 22 in an initial analysis of clinical trials. Read More
Life Edit receives $400K to find gene editing approaches for cystic fibrosis
Life Edit Therapeutics has received a $400,000 award from the Cystic Fibrosis Foundation to identify potential gene editing approaches to treat patients with cystic fibrosis. Read More
Pfizer starts evaluation of SARS-CoV-2 oral antiviral
Pfizer is advancing its clinical research of PF-07321332, a new investigational oral antiviral therapy against SARS-CoV-2, to evaluate the safety and efficacy of multiple ascending doses of the drug candidate. Read More
Model Medicines partners with Sandford Prebys Medical
Artificial intelligence drug discovery software developer Model Medicines has signed a deal with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets. Read More
Clover, Dynavax begin COVID-19 vaccine late-stage trials
Clover Biopharmaceuticals and Dynavax announced they have begun a phase II/III clinical trial to evaluate the efficacy of Clover's protein-based S-Trimer COVID-19 vaccine candidate. Read More
Rosalind launches web-based SARS-CoV-2 variant tracker
Rosalind has launched a web-based platform called Rosalind Diagnostic Monitoring for tracking SARS-CoV-2 variants and evaluating their effects on diagnostic tests. Read More
Safety board raises concern over AstraZeneca COVID-19 vaccine efficacy
Late in the day on March 22, the data safety monitoring board notified the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and AstraZeneca that it was concerned about information released by AstraZeneca that may result in an incomplete view of efficacy data. In response, AstraZeneca released a statement expressing the company's intention to work with the board and release results of the primary analysis within 48 hours. Read More
Dyadic, Medytox to develop COVID-19 vaccines against variants
Dyadic International and South Korean biopharmaceutical firm Medytox have partnered to co-develop C1-enabled vaccines and boosters that will immunize against COVID-19 variants. Read More
AbSci secures $125M in financing
Synthetic biology company AbSci has secured $125 million in financing that it plans to use to further develop its artificial intelligence platform for creating synthetic biology drugs. Read More
Thermo Fisher optimizes mass spec software, launches new Gibco media
Thermo Fisher Scientific announced that it plans to collaborate with Protein Metrics on mass spectrometry data analysis for biopharmaceutical and proteomics applications. The company also launched its new Gibco human plasma-like medium for more physiologically relevant cell culture models. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
